AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33828254 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily plus Pembrolizumab 200 mg every 3 weeks
Number of subjects: 40
Study 33828254 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 33828507 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided imagery training (CAIT)
Number of subjects: 1
Study 33828507 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subject
Number of subjects: 1
Study 33828518 — intervention group
Group type: EXPERIMENTAL
Intervention: Zika virus infection
Number of subjects: 406
Study 33828518 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Illness of Unidentified Origin (AIUO)
Number of subjects: 406
Study 33828518 — intervention group
Group type: COMPARATOR
Intervention: Dengue virus infection
Number of subjects: 406
Study 33828613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 0
Study 33828613 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 33829021 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring serum NET levels
Number of subjects: 0
Study 33829021 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulating the balance between NET formation and removal
Number of subjects: 0
Study 33829030 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced High-Volume Preparation for Colonoscopy
Number of subjects: 0
Study 33829030 — intervention group
Group type: COMPARATOR
Intervention: Conventional Low-Volume Preparation for Colonoscopy
Number of subjects: 0
Study 33829034 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Protein/Low Glycemic Index Diet
Number of subjects: 0
Study 33829034 — intervention group
Group type: COMPARATOR
Intervention: Conventional Diet
Number of subjects: 0
Study 33829237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice intake at 1 year old (120 mL per day)
Number of subjects: 783
Study 33829305 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) procedure comprising 3 cycles of brachial cuff inflation to 200 mmHg for 5 min followed by deflation to 0 mmHg for another 5 min, performed at study inclusion and repeated after 12 and 24 hours.
Number of subjects: 26
Study 33829305 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) procedure repeated after 12 and 24 hours.
Number of subjects: 26
Study 33829355 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-516 in combination with intravenous irinotecan (120 mg/m2), administered for five consecutive days followed by two days off.
Number of subjects: 0
Study 33829783 — intervention group
Group type: EXPERIMENTAL
Intervention: AG-270, a first-in-class oral MAT2A inhibitor
Number of subjects: 0
Study 33829783 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33829867 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher total screen exposure
Number of subjects: 250
Study 33829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Noergaard technique
Number of subjects: 151
Study 33829991 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) mapping
Number of subjects: 140
Study 33830058 — intervention group
Group type: EXPERIMENTAL
Intervention: iCST app intervention in addition to usual care
Number of subjects: 60
Study 33830058 — intervention group
Group type: COMPARATOR
Intervention: treatment-as-usual
Number of subjects: 60
Study 33830168 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy at 2 Gy/fraction concurrent with standard chemotherapy with or without adjuvant durvalumab.
Number of subjects: 27
Study 33830168 — intervention group
Group type: COMPARATOR
Intervention: Standard chemoradiation therapy (not explicitly detailed in the abstract).
Number of subjects: 27
Study 33830168 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-sparing technique with intensity-modulated radiation therapy to 70 Gy.
Number of subjects: 27
Study 33830342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with prior cetuximab
Number of subjects: 256
Study 33830342 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab without prior cetuximab
Number of subjects: 256
Study 33830342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab with neck dissection
Number of subjects: 256
Study 33830342 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab without neck dissection
Number of subjects: 256
Study 33830377 — intervention group
Group type: EXPERIMENTAL
Intervention: FACIT-Fatigue
Number of subjects: 2520
Study 33830399 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR measured before PCI
Number of subjects: 111
Study 33830399 — intervention group
Group type: EXPERIMENTAL
Intervention: QFR measured after PCI
Number of subjects: 111
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 5 mg
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 10 mg
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 7.5 mg
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 10 mg intermittent dosing (3 days on, 4 days off)
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 15 mg intermittent dosing (1 day on, 6 days off)
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 overall
Number of subjects: 39
Study 33830407 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP4132 pharmacokinetics
Number of subjects: 39
Study 33830871 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary VZV DNA detection using real-time PCR
Number of subjects: 50
Study 33830871 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominopelvic computed tomography (APCT)
Number of subjects: 50
Study 33830871 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 patients
Number of subjects: 50
Study 33831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose beetroot juice (BJ) supplementation (nitrate: 1.3 mmol/L)
Number of subjects: 60
Study 33831045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose beetroot juice (BJ) supplementation (nitrate: 4.3 mmol/L)
Number of subjects: 60
Study 33831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (BJ) supplementation (nitrate: 0.9 mmol/L)
Number of subjects: 60
Study 33831045 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (BJ) supplementation
Number of subjects: 60
Study 33831519 — intervention group
Group type: EXPERIMENTAL
Intervention: Passeo-18 Lux drug-coated balloon (DCB)
Number of subjects: 418
Study 33831732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 200 mg every 2 weeks intravenously for up to 48 weeks
Number of subjects: 20
Study 33831732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Number of subjects: 20
Study 33831812 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based teasing (WBT)
Number of subjects: 201
Study 33831901 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated administration of ephedrine or phenylephrine via the ADIVA algorithm
Number of subjects: 45
Study 33831901 — intervention group
Group type: EXPERIMENTAL
Intervention: ADIVA system with noninvasive continuous haemodynamic monitoring
Number of subjects: 45
Study 33832305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram risk threshold of 28% for low Global Health Status (GHS)
Number of subjects: 173
Study 33832305 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI <23, age >65 years, female sex
Number of subjects: 173
Study 33832305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram score ≥72
Number of subjects: 173
Study 33832305 — intervention group
Group type: EXPERIMENTAL
Intervention: C-statistics of the final predictive model
Number of subjects: 173
Study 33832543 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual family-based treatment (vFBT)
Number of subjects: 0
Study 33832565 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva specimen
Number of subjects: 19110
Study 33832565 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal swab (OPS)
Number of subjects: 19110
Study 33832565 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab (NPS)
Number of subjects: 19110
Study 33832610 — intervention group
Group type: EXPERIMENTAL
Intervention: SAVOR-TIMI 53 trial intervention
Number of subjects: 0
Study 33832610 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33832946 — intervention group
Group type: EXPERIMENTAL
Intervention: N-803 plus rituximab
Number of subjects: 0
Study 33832946 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous N-803 plus rituximab
Number of subjects: 0
Study 33832946 — intervention group
Group type: EXPERIMENTAL
Intervention: CITE-seq analysis
Number of subjects: 0
Study 33833048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 69
Study 33833048 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection based on KIR genotypes
Number of subjects: 69
Study 33834845 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 5116
Study 33834845 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5116
Study 33834847 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted stent implantation
Number of subjects: 10
Study 33835229 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 125 mg once daily plus letrozole 2.5 mg once daily
Number of subjects: 26
Study 33835265 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV‑2 IgG and IgM antibody tests using a high sensitivity/low specificity threshold
Number of subjects: 235
Study 33835265 — intervention group
Group type: COMPARATOR
Intervention: Positive controls with proven COVID-19
Number of subjects: 235
Study 33835265 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum samples from healthcare workers
Number of subjects: 235
Study 33835383 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 120 mg
Number of subjects: 459
Study 33835383 — intervention group
Group type: EXPERIMENTAL
Intervention: GMB 240 mg
Number of subjects: 459
Study 33835383 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 459
Study 33835628 — intervention group
Group type: EXPERIMENTAL
Intervention: Floatation-Reduced Environmental Stimulation Therapy (REST) for 90 minutes
Number of subjects: 0
Study 33835628 — intervention group
Group type: COMPARATOR
Intervention: Control condition (resting supine in a zero-gravity chair) for 90 minutes
Number of subjects: 0
Study 33835823 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Number of subjects: 0
Study 33835823 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon catheter ablation
Number of subjects: 0
Study 33835826 — intervention group
Group type: EXPERIMENTAL
Intervention: IRONMAN registry strategies for site selection, recruitment, engagement, and retention.
Number of subjects: 0
Study 33835826 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated collection of clinical outcomes, patient-reported outcomes, epidemiologic data, and biospecimens.
Number of subjects: 0
Study 33835830 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based breathing techniques
Number of subjects: 0
Study 33835830 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33835866 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks until disease progression, unacceptable toxicity, loss of clinical benefit, or patient/physician decision
Number of subjects: 1004
Study 33835866 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 1004
Study 33835936 — intervention group
Group type: EXPERIMENTAL
Intervention: Email-based dialectical behavioral therapy (DBT)
Number of subjects: 0
Study 33835936 — intervention group
Group type: COMPARATOR
Intervention: In-person dialectical behavioral therapy (DBT)
Number of subjects: 0
Study 33835977 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-positive MPM
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in PD-L1-negative MPM
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious treatment-related adverse events
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 3-4 treatment-related events
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Common grade 3-4 treatment-related events
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related death
Number of subjects: 118
Study 33836153 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of pembrolizumab
Number of subjects: 118
Study 33836187 — intervention group
Group type: EXPERIMENTAL
Intervention: AAP model using 3 criteria (both parents born outside the EU, low weight at 1 year, weaning to cow's milk without supplemental iron)
Number of subjects: 568
Study 33836187 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly derived simple prediction tool (≥1 criterion among the 3 previous plus duration of iron-rich formula consumption <12 months)
Number of subjects: 568
Study 33836262 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra Virgin Olive Oil (EVOO)
Number of subjects: 84
Study 33836262 — intervention group
Group type: COMPARATOR
Intervention: No EVOO treatment
Number of subjects: 84
Study 33836671 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for high-grade gliomas
Number of subjects: 35
Study 33836671 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure diary
Number of subjects: 35
Study 33836671 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly neurologist consultations
Number of subjects: 35
Study 33836889 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic cell transplantation (alloHCT) covered by state Medicaid programs
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Legislative policies mandating coverage of routine medical costs for patients in clinical trials
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Acceptance of out-of-state Medicaid insurance
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Coverage for travel and lodging for the patient and one caregiver
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Medicaid fee-for-service plans
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Insurance authorization process for alloHCT
Number of subjects: 10
Study 33836889 — intervention group
Group type: COMPARATOR
Intervention: Legislative policy for access to clinical trials and out-of-state benefits
Number of subjects: 10
Study 33836987 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 33
Study 33837055 — intervention group
Group type: EXPERIMENTAL
Intervention: Belapectin (2, 4, or 8 mg/kg IV 60 min before pembrolizumab) + pembrolizumab (200 mg IV every 3 weeks for five cycles)
Number of subjects: 20
Study 33837055 — intervention group
Group type: EXPERIMENTAL
Intervention: Belapectin + pembrolizumab
Number of subjects: 20
Study 33837786 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention combining MOST and CBPR principles, cost under $250 per person.
Number of subjects: 0
Study 33837912 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized hospitalization in the COVID-19 unit of the Paracelsus Medical University Salzburg, irrespective of symptoms.
Number of subjects: 0
Study 33838339 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 478
Study 33838463 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF audiometry at 9, 10, 11.2, 12.5, 14 and 16 kHz
Number of subjects: 126
Study 33838463 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF audiometry at 14 kHz
Number of subjects: 126
Study 33838463 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF audiometry at 16 kHz
Number of subjects: 126
Study 33838463 — intervention group
Group type: EXPERIMENTAL
Intervention: EHF audiometry comparing age groups 6-9 years and 10-14 years at 16 kHz
Number of subjects: 126
Study 33838463 — intervention group
Group type: COMPARATOR
Intervention: EHF audiometry comparing right and left ears
Number of subjects: 126
Study 33838463 — intervention group
Group type: COMPARATOR
Intervention: EHF audiometry comparing genders
Number of subjects: 126
Study 33838625 — intervention group
Group type: EXPERIMENTAL
Intervention: G207 (oncolytic herpes simplex virus type 1)
Number of subjects: 12
Study 33838625 — intervention group
Group type: EXPERIMENTAL
Intervention: G207
Number of subjects: 12
Study 33839064 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-Tat immunity
Number of subjects: 0
Study 33839064 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic approaches aiming at reinforcing anti-Tat immunity
Number of subjects: 0
Study 33839074 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-directed therapy (monotherapy)
Number of subjects: 1207
Study 33839487 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Sensitivity Index (DSI)
Number of subjects: 0
Study 33839487 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical and cognitive concerns (DSPCC)
Number of subjects: 0
Study 33839487 — intervention group
Group type: EXPERIMENTAL
Intervention: Social concerns (DSSC)
Number of subjects: 0
Study 33839905 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole food-based low-calorie diet combined with app-based digital education and behavioral change program
Number of subjects: 24
Study 33840050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal
Number of subjects: 30
Study 33840050 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Number of subjects: 30
Study 33840068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month community intervention consisting of group education for type 2 diabetes knowledge, diet, exercise in combination with usual diabetes care
Number of subjects: 364
Study 33840068 — intervention group
Group type: COMPARATOR
Intervention: Usual diabetes care alone (control)
Number of subjects: 364
Study 33840068 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month community intervention
Number of subjects: 364
Study 33840295 — intervention group
Group type: EXPERIMENTAL
Intervention: Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120
Study 33840295 — intervention group
Group type: COMPARATOR
Intervention: Before Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120
Study 33840295 — intervention group
Group type: EXPERIMENTAL
Intervention: After Gagne Index/Epic SlicerDicer intervention
Number of subjects: 120
Study 33840396 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM)
Number of subjects: 91
Study 33840477 — intervention group
Group type: EXPERIMENTAL
Intervention: IVC reconstruction
Number of subjects: 17
Study 33840726 — intervention group
Group type: EXPERIMENTAL
Intervention: Steatohepatitis
Number of subjects: 420
Study 33840726 — intervention group
Group type: COMPARATOR
Intervention: No FLD
Number of subjects: 420
Study 33840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatments
Number of subjects: 22492
Study 33840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based quadruple therapy
Number of subjects: 22492
Study 33840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 22492
Study 33840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment compliance
Number of subjects: 22492
Study 33840725 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer treatment durations
Number of subjects: 22492
Study 33840743 — intervention group
Group type: EXPERIMENTAL
Intervention: High Total Cholesterol (TC)
Number of subjects: 2312
Study 33840743 — intervention group
Group type: EXPERIMENTAL
Intervention: High Low-Density Lipoprotein Cholesterol (LDL-C)
Number of subjects: 2312
Study 33840749 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitatively prescribed PD-AFO
Number of subjects: 10
Study 33840749 — intervention group
Group type: COMPARATOR
Intervention: Original AFO
Number of subjects: 10
Study 33840791 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vascular occlusion
Number of subjects: 23
Study 33840791 — intervention group
Group type: EXPERIMENTAL
Intervention: Choroidopathy
Number of subjects: 23
Study 33840791 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal vasculitis
Number of subjects: 23
Study 33840791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual acuity
Number of subjects: 23
Study 33841012 — intervention group
Group type: EXPERIMENTAL
Intervention: Korea Red Ginseng (KRG) 2,000 mg/day for 30 days
Number of subjects: 94
Study 33841012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 33841184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 0
Study 33842385 — intervention group
Group type: EXPERIMENTAL
Intervention: Different sequencing approaches targeting different 16S rRNA variable regions
Number of subjects: 412
Study 33842385 — intervention group
Group type: EXPERIMENTAL
Intervention: Different DNA processing and sequencing approaches
Number of subjects: 412
Study 33842385 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-processing and re-sequencing of microbiome
Number of subjects: 412
Study 33842418 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0